

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書 籍 名	出版社名	出版地	出版年	ページ
<u>Kameda H</u>	DLI caused by disease-modifying antirheumatic drugs: What are the characteristics of DLI by disease-modifying antirheumatic drugs?	Hanaoka M, Nakamura H, Aoshiba K eds.	Drug-induced lung injury	Springer	Singapore	2017	165-176
Meehansan J, Subpayarn U, Mayumi Komine M, <u>Ohtsuki M</u>	Pathogenic Role of Cytokines and Effect of Their Inhibition in Psoriasis	Chiriac A ed.	Psoriasis: An Interdisciplinary Approach to	IntechOpen	United Kingdom	2017	41-60
<u>森田明理</u>	乾癬性関節炎の皮膚科医としてのプライマリケアは？	宮地良樹 編	専門医でも聞きたい皮膚科診療100の質問	メディカルレビュー社	大阪	2017	98-99
<u>亀田秀人</u>	治療(特に分子標的療法)に関連する呼吸器感染症	三嶋理晃, 藤田次郎 編	呼吸器疾患診断治療アプローチ 呼吸器感染症	中山書店	東京	2017	279-284
<u>亀田秀人</u>	解熱・鎮痛薬、抗炎症薬	堀正二, 菅野健太郎, 門脇孝, 乾賢一, 林昌洋 編	治療薬ハンドブック	じほう	東京	2018	1122-1152
<u>亀田秀人</u>	ステロイド等価換算	山本一彦 編	ステロイドの選び方・使い方ハンドブック改訂第3版	羊土社	東京	2018	27-29
<u>亀田秀人</u>	薬物相互作用	山本一彦 編	ステロイドの選び方・使い方ハンドブック改訂第3版	羊土社	東京	2018	30-33

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Fukuda T, Umezawa Y, Teraojo S, Yonenaga T, Asahina A, Nakagawa H, Fukuda K.	Initial Experience of Using Dual-Energy CT with an Iodine Overlay Image for Hand Psoriatic Arthritis: Comparison Study with Contrast-enhanced MR Imaging.	Radiology	284(1)	134-142	2017
Hayashi M, Yanaba K, Umezawa Y, Asahina A, Nakagawa H.	Impact of anti-tumor necrosis factor- $\alpha$ agents on serum levels of KL-6 and surfactant protein-D in patients with psoriasis.	J Dermatol	44(9)	1063-1066	2017
Momose M, Asahina A, Hayashi M, Yanaba K, Umezawa Y, Nakagawa H.	Biologic treatments for elderly patients with psoriasis.	J Dermatol	44(9)	1020-1023	2017
Honda H, Umezawa Y, Kikuchi S, Yanaba K, Fukuchi O, Ito T, Nobeyama Y, Asahina A, Nakagawa H.	Switching of biologics in psoriasis: Reasons and results.	J Dermatol	44(9)	1015-1019	2017
Asahina A, Kubo N, Umezawa Y, Honda H, Yanaba K, Nakagawa H.	Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: Response to therapy with biologics.	J Dermatol	44(10)	1112-1121	2017
Hayashi M, Yanaba K, Umezawa Y, Asahina A, Nakagawa H.	Superiority of magnetic resonance imaging over conventional radiography in the early diagnosis of psoriatic arthritis.	J Dermatol	44(10)	e232-e233	2017
Fukuda T, Umezawa Y, Asahina A, Nakagawa H, Furuya K, Fukuda K.	Dual energy CT iodine map for delineating inflammation of inflammatory arthritis.	Eur Radiol	27(12)	5034-5040	2017
Asahina A, Umezawa Y, Momose M, Honda H, Yanaba K, Nakagawa H.	New onset or transition of disease state of psoriatic arthritis during treatment with ustekinumab: A single-center retrospective study.	J Dermatol	44(12)	1380-1384	2017
Asahina A, Fukuda T, Ishiura Y, Yaginuma A, Yanaba K, Umezawa Y, Nakagawa H.	Usefulness of dual-energy computed tomography for the evaluation of early-stage psoriatic arthritis only accompanied by nail psoriasis.	J Dermatol	44(12)	e326-e327	2017
Asahina A, Nakagawa H.	Comment on "Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review".	J Am Acad Dermatol	77(6)	e167-e168	2017
Momose M, Asahina A, Umezawa Y, Nakagawa H.	Long-term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: A single-center experience.	J Dermatol	45(3)	318-321	2018
Nobeyama Y, Umezawa Y, Nakagawa H.	Silencing of homeobox A5 gene in the stratum corneum of psoriasis.	Exp Dermatol	26(11)	1068-1074	2017

<u>Terui T</u> , Kobayashi S, Okubo Y, Murakami M, Hirose K, Kubo H.	Efficacy and safety of guselkumab, an anti-interleukin 23 monoclonal antibody, for palmoplantar pustulosis: A randomized clinical trial.	JAMA Dermatol	154(3)	309-316	2018
Guenther L, Warren RB, Cather JC, Sofen H, Poulton Y, Lebwohl M, <u>Terui T</u> , Potts Bleakman A, Zhu B, Burge R Reich K, van de Kerkhof P.	Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12 week results from two Phase 3 trials.	J Eur Acad Dermatol Venerol	31(11)	1867-1875	2017
Nakajima H, Serada S, Fujimoto M, Naka T, <u>Sano S</u> .	Leucine-rich $\alpha$ -2 glycoprotein is an innovative biomarker for psoriasis.	J Dermatol Sci	86(2)	170-174	2017
Yamanaka K, Yamagiwa A, Akeda T, Kondo M, Kakeda M, Habe K, Imafuku S, <u>Sano S</u> , Mizutani H.	Neutrophils are not the dominant interleukin-17 producer in psoriasis.	J Dermatol	44(7)	e170-e171	2017
Charruyer A, Fong S, Vitkov GG, Sklar S, Tabernick L, Taneja M, Caputo M, Soeung C, Yue L, Uchida Y, Arron ST, Horton KM, Foster RD, <u>Sano S</u> , North JP, Ghadially R.	Brief Report: Interleukin-17A-Dependent Asymmetric Stem Cell Divisions Are Increased in Human Psoriasis: A Mechanism Underlying Benign Hyperproliferation.	Stem Cells	35(8)	2001-2007	2017
<u>Sano S</u> .	Proposal for long-term protocols after Psoriasis Area and Severity Index clearance with initial biologic therapy: Happily ever after with or without biologics in psoriasis therapy.	J Dermatol	44(10)	e234-e235	2017
Nakajima K, <u>Sano S</u> .	Mouse models of psoriasis and their relevance.	J Dermatol	45(3)	252-263	2018
<u>Sano S</u> , Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H.	Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.	J Dermatol	45(5)	529-539	2018
<u>Yamamoto T</u> , Ohtsuki M, <u>Sano S</u> , Igarashi A, Morita A, Okuyama R, Kawada A.	Prevalence and current therapies of psoriatic arthritis in Japan: a survey by the Japanese Society of Psoriasis Research in 2016.	J Dermatol	44(6)	e121	2017
<u>Yamamoto T</u> , Kawada A.	Clinical characteristics of Japanese patients with psoriatic arthritis: comparison with East Asian countries.	J Dermatol	45(3)	273-278	2018
Blauvelt A, Papp KA, Sofen H, Augustin M, Yosipovitch G, <u>Katoh N</u> , Mrowietz U, <u>Ohtsuki M</u> , Poulin Y, Shrom D, Burge R, Sefton K, Mallbris L, Gordon KB.	Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.	J Eur Acad Dermatol Venerol	31(6)	1004-1013	2017

Torii H, Nakano M, Yano T, Kondo K, <u>Nakagawa H</u> ; SPREAD Study Group.	Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: Results of the SPREAD study.	J Dermatol	44(5)	552-559	2017
<u>Ohtsuki M</u> , Okubo Y, Komine M, Imafuku S, Day RM, Chen P, Petric R, Maroli A, Nemoto O.	Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial	J Dermatol	44(8)	873-884	2017
<u>Ohtsuki M</u> , <u>Morita A</u> , Igarashi A, Imafuku S, Tada Y, Fujita H, Fujishige A, Yamaguchi M, Teshima R, Tani Y, <u>Nakagawa H</u> .	Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch.	J Dermatol	44(10)	1105-1111	2017
Shear NH, Paul C, Blauvelt A, Gooderham M, Leonard C, Reich K, <u>Ohtsuki M</u> , Pangallo B, Xu W, Ball S, Ridenour T, Torisu-Itakura H, Agada N, Mallbris L.	Safety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions from 11 Clinical Trials.	J Drugs Dermatol	17(2)	200-206	2018
Papp KA, Leonardi CL, Blauvelt A, Reich K, Korman NJ, <u>Ohtsuki M</u> , Paul C, Ball S, Cameron GS, Erickson J, Zhang L, Mallbris L, Griffiths CEM.	Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).	Br J Dermatol	178(3)	674-681	2018
Papp KA, Bachelez H, Blauvelt A, Winthrop KL, Romoiti R, <u>Ohtsuki M</u> , Acharya N, Braun DK, Mallbris L, Zhao F, Xu W, Walls CD, Strober B.	Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis.	Br J Dermatol	177(6)	1537-1551	2017
Kanekura T, Seishima M, Honma M, Etou T, Eto H, Okuma K, Okubo Y, Yamaguchi Y, Kambara T, Mabuchi T, Suga Y, <u>Mori ta A</u> , Yamanishi K, Tsuruta D, Itoh K, Yamaji K, Ikeda S.	Therapeutic depletion of myeloid lineage leukocytes by adsorptive apheresis for psoriatic arthritis: Efficacy of a non-drug intervention for patients refractory to pharmacologics.	J Dermatol	44(12)	1353-1359	2017
Saeki H, <u>Nakagawa H</u> , Nakajako K, Ishii T, Morisaki Y, Aoki T, Cameron GS, Osuntokun OO; Japanese Ixekizumab Study Group.	Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).	J Dermatol	44(4)	355-362	2017

Ogawa E, <u>Okuyama R</u> , Seki T, Kobayashi A, Oiso N, Muto M, <u>Nakagawa H</u> , Kawada A.	Epidemiological survey of patients with psoriasis in Matsumoto city, Nagano Prefecture, Japan.	J Dermatol	45(3)	314-317	2018
Ogawa E, Sato Y, Minagawa A, <u>Okuyama R</u> .	Pathogenesis of psoriasis and development of treatment.	J Dermatol	45(3)	264-272	2018
Tokuda H, Harigai M, <u>Kameda H</u> , Tomono K, Takanashi N, Watanabe A, Tasaka S, Suda T, Tateda K, Kadota J.	Consensus statements for medical practice : Biological agents and lung disease	Respir Invest	55(3)	229-251	2017
Ito H, Ogura T, Hirata A, Takenaka S, Mizushima K, Fujisawa Y, Katagiri T, Hayashi N, <u>Kameda H</u> .	Global assessments of disease activity are age-dependent determinant factors of clinical remission in rheumatoid arthritis.	Semin Arthritis Rheum	47(3)	310-314	2017
Hirata A, Ogura T, Hayashi N, Takenaka S, Ito H, Mizushina K, Fujisawa Y, Yamashita N, Nakahashi S, Imamura M, Kujime R, <u>Kameda H</u> .	MTX use in Japanese patients with rheumatoid arthritis (Reply to letter to the editor).	Arthritis Care Res	in press		2017
Hirata A, Ogura T, Hayashi N, Takenaka S, Ito H, Mizushina K, Fujisawa Y, Yamashita N, Nakahashi S, Imamura M, Kujime R, <u>Kameda H</u> .	Concordance of Patient-Reported Joint Symptoms, Physician-Examined Arthritic Signs, and Ultrasound-Detected Synovitis in Rheumatoid Arthritis.	Arthritis Care Res	69(6)	801-806	2017
Zenke Y, Ohara Y, Kobayashi D, Arai S, <u>Kishimoto M</u> , Okada M, Eto H.	Nail findings in patients with psoriatic arthritis: A cross-sectional study with special reference to transverse grooves.	J Am Acad Dermatol	77(5)	863-867	2017
Kojima M, Nakayama T, Otani T, Hasegawa M, Kawahito Y, Kaneko Y, <u>Kishimoto M</u> , Hirata S, Seto Y, Endo H, Ito H, Kojima T, Nishida K, Matsushita I, Tsutani K, Igarashi A, Kamatani N, Miyasaka N, Yamanaka H.	Integrating patients' perceptions into clinical practice guidelines for the management of rheumatoid arthritis in Japan.	Mod Rheumatol	27(6)	924-929	2017
Molto A, Gossec L, Meghathani B, Landewé RBM, van der Heijde D, Atagunoz P, Elzorkany BK, Akkoc N, Kiltz U, Gu J, Weickert JCC, Dougados M; ASAS-FLARE study group ( <u>Kishimoto M</u> , et al).	An Assessment in Spondyloarthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS.	Ann Rheum Dis	77(1)	124-127	2018

van der Heijde D, Gladman DD, <u>Kishimoto M</u> , Okada M, Rathmann SS, Moriarty SR, Shuler CL, Carlier H, Benichou O, Mease PJ.	Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase II Study (SPIRIT-P1).	J Rheumatol	45(3)	367-377	2018
Coates LC, <u>Kishimoto M</u> , Gottlieb A, Shuler CL, Lin CY, Lee CH, Mease PJ.	Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1.	RMD Open	3(2)	e000567	2017
Hattori Y, Kojima T, <u>Kaneko A</u> , Kida D, Hirano Y, Fujibayashi T, Yabe Y, Oguchi T, Kanayama Y, Miyake H, Kato T, Takagi H, Hayashi M, Ito T, Shioura T, Takahashi N, Ishikawa H, Funahashi K, Ishiguro N.	High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab.	Mod Rheumatol	28(1)	119-125	2018
Asai S, Fujibayashi T, Oguchi T, Hanabayashi M, Hayashi M, Matsubara H, Ito T, Yabe Y, Watanabe T, Hirano Y, Kanayama Y, <u>Kaneko A</u> , Kato T, Takagi H, Takahashi N, Funahashi K, Takemoto T, Asai N, Watanabe T, Ishiguro N, Kojima T.	Predictors of biologic discontinuation due to insufficient response in patients with rheumatoid arthritis who achieved clinical remission with biologic treatment: A multicenter observational cohort study.	Mod Rheumatol	28(2)	221-226	2018
Hattori Y, Kida D, <u>Kaneko A</u> .	Comparison of physical function in early rheumatoid arthritis patients treated with biologics for 1 year who achieved clinical remission or low disease activity.	Clin Rheumatol	36(11)	2607-2612	2017
Hattori Y, Kida D, <u>Kaneko A</u> .	Normal serum matrix metalloproteinase-3 levels can be used to predict clinical remission and normal physical function in patients with rheumatoid arthritis.	Clin Rheumatol	in press		2017
百瀬まみ, 梅澤慶紀, 朝比奈昭彦, 中川秀己	生物学的製剤を使用している乾癬患者におけるIGRA検査(interferon-releasing assay)の経時的変化	日本皮膚科学会雑誌	127(8)	1775-1779	2017
梅澤慶紀, 朝比奈昭彦, 中川秀己	乾癬 重症度評価法	皮膚科の臨床	59(6)	837-846	2017
朝比奈昭彦	生物学的製剤update-臨床のためのポイント解説-アダリムマブ	Derma	263	21-27	2017
梅澤慶紀	生物学的製剤update-臨床のためのポイント解説-プロダリムマブ	Derma	263	53-62	2017

梅澤慶紀, 中川秀己	皮膚科 乾癬-乾癬性関節炎に対する生物学的製剤の効果とその位置づけ	アレルギー・免疫	24(12)	598-609	2017
梅澤慶紀	病気について知りたい!! 臨床講座 乾癬	PharmaTribune	9(12)	5-9	2017
梅澤慶紀, 中川秀己	乾癬治療薬の作用機序	日本臨床	76(1)	2-7	2018
中川秀己	乾癬の臨床分類と重症度評価	日本臨床	76(1)	9-15	2018
唐川太, 中川秀己	乾癬・乾癬性関節炎の疫学	日本臨床	76(1)	16-21	2018
照井正	PDE阻害剤. オテズラ錠10mg, 同 20mg, 同30mg.	医薬ジャーナル	54(S-1)	59-67	2018
佐野栄紀	乾癬の免疫学的病態	日本臨床	76(1)	22-27	2018
亀田秀人	乾癬の症状・診断・鑑別診断 乾癬性関節炎	日本臨床	76(1)	61-67	2018
小宮根真弓, 大槻マミ太郎	乾癬の治療 治療総論	日本臨床	76(1)	86-90	2018
小川英作, 佐藤 勇樹, 奥山隆平	乾癬の治療 生物学的製剤 TNF-阻害薬とIL-12/23阻害薬	日本臨床	76(1)	128-134	2018
石井まどか, 藤田英樹, 照井正	乾癬の治療 生物学的製剤 IL-17阻害薬	日本臨床	76(1)	136-141	2018
岸本恵美, 大槻マミ太郎	皮膚科におけるシクロスポリン療法の位置づけ	Visual Dermatology	16(9)	852-859	2017
中川秀己	乾癬性関節炎の早期診断・治療を目指して	Visual Dermatology	17(3)	212-213	2017
八木沼彩, 朝比奈昭彦, 梅澤慶紀, 中川秀己	爪乾癬のみの乾癬性関節炎	Visual Dermatology	17(3)	218-219	2017
浅井令奈, 梅澤慶紀, 朝比奈昭彦, 中川秀己	ウステキヌマブからアダリムマブへの切り替えが有効であった乾癬性関節炎	Visual Dermatology	17(3)	228-231	2017
中川秀己	乾癬性関節炎の早期診断・治療を目指して	クリニシアン	64(7)	566-577	2017
佐野栄紀	関節症性乾癬(psoriatic arthritis:PsA)の最新知見 皮膚科の立場から	クリニシアン	64(7)	644-650	2017
大槻マミ太郎, 佐伯秀久, 板倉仁枝, 中川秀己	イクセキズマブの薬理学的特性および有効性・安全性	日本皮膚科学会雑誌	127(10)	2325-2338	2017
大槻マミ太郎, 五十嵐 敦之	乾癬に対するメトトレキサート使用症例全国調査 日本皮膚科学会による生物学的製剤使用承認施設を対象とした使用実態調査(その2)	日本皮膚科学会雑誌	128(2)	169-176	2018
大槻マミ太郎	皮膚疾患治療のポイント 乾癬に対するアプレミラスト内服療法	臨床皮膚科	71(5)	114-119	2017

山本俊幸	非典型例をどう考えるか 関節症性乾癬	Visual Dermatology	16(7)	690-693	2017
山本俊幸	皮膚科の検査とその評価法 関節症性乾癬	皮膚科の臨床	59(6)	862-866	2017
山本俊幸	病態・治療Q&A 脊椎関節炎 乾癬性関節炎(PsA)患者の皮膚症状についてお教えください(Q&A)	臨床のあゆみ	103	15-16	2017
山本俊幸	乾癬性関節炎(関節症性乾癬)研究の変遷	皮膚病診療	39(12)	1230-1235	2017
山本俊幸	乾癬の最重症型	皮膚病診療	40(1)	91-94	2018
小田隆夫, 村松伸之介, 加藤裕史, 西田絵美, 森田明理	間質性肺炎の既往をもつ関節症性乾癬に生物学的製剤が奏効した1例	皮膚科の臨床	59(4)	443-446	2017
森田明理	乾癬に対する生物学的製剤の効果と血中濃度	Derma	263	4-75	2017
亀田秀人, 西田圭一郎, 南木敏宏, 渡辺彰, 大島行哉, 桃原茂樹	関節リウマチに対するセルトリズマブペゴルの安全性及び有効性: 使用成績調査の中間解析	日本臨床免疫学会誌	40(3)	196-205	2017
亀田秀人	関節痛の鑑別 症状と身体診察でどこまで鑑別可能か	成人病と生活習慣病	47(9)	1065-1070	2017
亀田秀人	Tight control strategyがcost effectiveである	リウマチ科	58(6)	590-592	2017
亀田秀人	Patient-reported outcome (PRO) の重要性と課題	Joint And Kinase Frontier		14-15	2017
亀田秀人	免疫疾患と眼炎症 序	炎症と免疫	26(2)	127	2018
亀田秀人	Baricitinibのエビデンス	リウマチ科	59(3)	233-237	2018
須田万勢, 岸本暢将	乾癬性関節炎におけるclazakizumabの有効性	リウマチ科	58(1)	78-84	2017
須田万勢, 岸本暢将	乾癬性関節炎の治療における生物学的製剤の位置づけ 2015年GRAPPA、EULARのガイドライン治療推奨を踏まえて	Derma	263	89-97	2017
岸本暢将	骨関節内科 実践編: リウマチ膠原病的アプローチ 脊椎関節炎	Medicina	54(13)	2238-2243	2017
川上玲奈, 福田健志, 福田彦彦	Dual energy CTヨードマップによる乾癬性関節炎の診断と治療効果判定	INNERVISION	33(3)	56-58	2018